Clinical trial

Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

NCT01618370

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Radium-223 dichloride (BAY88-8223) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-07-22

PhasePHASE3

Conditions

Prostatic Neoplasmsunresolved

Interventions

Radium-223 dichloride (BAY88-8223)DRUG

Sponsors & collaborators

Bayerlead sponsor

Mapped research locations

MilanLombardy, Italy4 ParisFrance3 BarcelonaBarcelona, Spain3 TorontoOntario, Canada2 MadridSpain2 PragueCzechia2 MontpellierFrance2 LilleFrance2 OsloNorway2 MadridMadrid, Spain2 Mexico CityMexico City, Mexico2 LondonUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01618370 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.